Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin.
The United States Food and Drug Administration (FDA) has received numerous reports of serious adverse events, including death, in patients using fentanyl transdermal systems (FTS). To gain a better understanding of these problems, the current research focuses on the in vitro characterization of fentanyl reservoir (Duragesic) and matrix (Mylan) systems with respect to drug release and skin permeation under conditions of elevated temperature and compromised skin. In addition, different synthetic membrane barriers were evaluated to identify the one that best simulates fentanyl skin transport, and thus may be useful as a model for these systems in future studies. The results indicate that reservoir and matrix FTS are comparable when applied to intact skin at normal skin temperature but the kinetics of drug delivery are different in the two systems. At 40 degrees C, the permeation rate of fentanyl was twice that seen at 32 degrees C over the first 24 h in both systems; however, the total drug permeation in 72 h is significantly higher in the reservoir FTS. When applied to partially compromised skin, matrix FTS has a greater permeation enhancement effect than reservoir FTS. The intrinsic rate limiting membrane of the reservoir system served to limit drug permeation when the skin (barrier) permeability was compromised. Different ethylene vinyl acetate membranes were shown to have fentanyl permeability values encompassing the variability in human skin. Results using the in vitro model developed using synthetic membranes suggest that they mimic the effect of compromised skin on fentanyl permeability. Especially for highly potent drugs such as fentanyl, it is important that patients follow instructions regarding application of heat and use of the product on compromised skin.
Prodduturi
Suneela
S
Aizant Drug Research Solutions Private Limited, Sy No. 172 & 173 Apparel Park Road, Dulapally Village, Hyderabad Quthbullapur, Mandal 50014, India.
Sadrieh
Nakissa
N
Wokovich
Anna M
AM
Doub
William H
WH
Westenberger
Benjamin J
BJ
Buhse
Lucinda
L
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006358:Hot Temperature; D006801:Humans; D066298:In Vitro Techniques; D012867:Skin / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D012869:Skin Absorption; D012995:Solubility
D000701:Analgesics, Opioid; D005283:Fentanyl